

ATTORNEY DOCKET NO. 09172.0006U1
Application Serial No. 10/625,645
SHEET 1 OF 1/8

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/625,645			
Filing Date	July 22, 2003			
First Named Inventor	Samual Christian			
Group Art Unit	1623			
Examiner Name	Leigh C. Maier			

Examiner's Initials	Cite No.	Document No.	U:S: PATENT DOC Date	Name	Class	Subclass	Filing Date (if appropriate
LCM	A1*	3,929,813	December 30, 1975	Bodor	546	261	<u>арргорната</u>
TCW	A2*	3,962,447	June 8, 1976	Bodor	424	263	
~~~	_A3_	5,380,837	January 10, 1995	Nakada et al	536	17.9.	
LCM	A4	5,639,737	June 17, 1997	Rubin	514	53	<u> </u>
LCM	A5*	6,339,064	January 15, 2002	McDevitt et al.	514	42	
LCM	A6	6,548,484	April 15, 2003	Christian	514	25	
LCM	A7	2006/0189547	August 24, 2006	Christian	514	23	
Examiner	Signatu	re:	Date 0	onsidered:			

	- C' - C		TENT DOCUMEN	TS	
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
LCM	A8*	WO 97/28174	August 7, 1997	Oehrlein	
LCM	A9*	WO 01/97244	October 25, 2007	Christian	
Examiner	Signature:		Date Considere	ed:	<u> </u>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

swy in the		NON-PATENT DOCUMENTS
Examin er's Initials	Cite No.	Non-Patent Citations (Include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
LCM	A10*	Alexander et al., "Role of conjugation and red blood cells for inactivation of ciculating catecholamines," Am. J. Physiol. 247(1):R203-R207 (1984)
LCM	A11*	Alvarado et al., "Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro," <i>Biochim. Biophys. Acta</i> 56:170-172 (1960)
LCM	A12*	Arita et al., "Studies on uptake of phenyl glycosides as inhibitors of D-glucose uptake by Rhesus monkey kidney cells," J. Biochem. 88:1399-1406 (1980)
LCW	A13*	Barnett et al., "Structural requirements for binding to the sugar transport system of the human erythrocyte," Biochem. J. 131:211-221 (1973)
LCM	A14*	Barnett et al., "Highlights of D1 dopamine receptor antagonist research," Neurochem. Int. 20 (Suppl.):119S-122S (1992)
LCM	A15*	Bencsics et al., "Dopamine, as well as, norepinephrine, is a link between noradrenergic nerve terminals and splenocytes," <i>Brain Res.</i> 761(2):236-243 (1997)

Examiner Signature:				Date Considered:	9-24-07
EXAMINER: Initial if reficitation if not in conformance	erence e and n	considered of consider	, whether or no	ot citation is in conforman	ce with MPEP 609; Draw line through communication to applicant.
647876				opy of this form with field (	communication to applicant.

DWP

# ATTORNEY DOCKET NO. 09172.0006U1 Application Serial No. 10/625,645 SHEET 2 OF X8

	Comple	ete if Known
INFORMATION DISCLOSURE	Application Number	10/625,645
STATEMENT LIST	Filing Date	July 22, 2003
		Samual Christian
(Use as many sheets as necessary)		1623
	Examiner Name	Leigh C. Maier

	A16*	Berger et al., "Synthesis and receptor affinities of some conformationally restricted
LCM		analogues of the dopamine D1 selective ligand
100,00		(5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl- 1 H-3-benzazepin-7-ol," J. Med.
ļ	1.55	(1989)
LCM	A17*	Brewster et al., "trans-10,11-dihydroxy-5,6,7,8,12b-hexahydrobenzo[a]phen -anthridine: A
<b></b>	1.10=	highly potent selective dopamine D1 full agonist," J. Med. Chem. 33:1756-1764 (1990)
LCM	A18*	Bodor et al., "Elimination of a quaternary pyridinium salt delivered as its
	110+	dihydropyridine," J. Pharr. Sci, 67(5):685 (1978)
	A19*	Bodor, "Novel Approaches for the Design of Membrane Transport Properties of Drugs"
LCM		In: "Design of Biopharmaceutical Properties Through Prodrugs and Analogs", Ed. E.B.
		Roche et al. APhA Academy of Pharmaceutical Sciences, Washington, D.C., p. 98-
	A20*	135 (1976)
LCM	AZU	Bodor et al., "Site-specific, sustained release of drugs to the brain," Science 214:1370-
<del></del>	A 21 #	1372 (1981)
LCM	A21*	Bodor et al., "Redox delivery systems for brain-specific, sustained release of
	A22*	dopamine," Science 221:65-67 (1983)
LCM	AZZ	Casagrande et al., "Synthesis and chemical properties of lbopamine and of related
_ ` `		esters of N-substituted dopamines: Synthesis of Ibopamine metabolites,"
<u> </u>	A23*	Arzneim. Forsch. 36(2a):291-303 (1986)
LCM	AZ3	Chen et al., "Transport-dependent accessibility of a cytoplasmic loop cysteine in
<del></del>	A24*	human dopamine transporter" J. Biol. Chem. 275(3):1608-1614 (2000)
LCM	724	Choi et al., "Novel 3-aminomethyland 4-aminopiperidine analogues of
um	İ	1[2-(diphenylmethoxy)ethy1]-4-(3-phenylpropyl)piperazines: Synthesis and
	A25*	evaluation as dopamine transporter ligands," J. Med. Chem. 43(2):205-213 (2000)
LCM		Clarkson et al., "Immortalized dpamine neurons: A model to study neurotoxicity and
	A26*	neuroprotection," Proc. Soc. Exp. Biol. Med. 222(2):157-163 (1999)
104	1120	Claustre et al., "Conjugation and deamination of circulating dopamine: Relationship between sulfated and free dopamine in man," J. Auton, Nerv. Syst. 29(2):175-182
LCM		(1990)
1 614	A27*	Coffey et al., "[3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of
LCM		tonicity and buffer composition," J. Neurosci. Methods 51(1):23-30 (1994)
LCM	A28	Czarnocki et al. "Enantiselective synthesis of (R)-(-)-Laudanosine and (R)-(-)-Glaucine
ШМ		from L-Ascorbic Acid," Tetrahedron: Assymetry, 7(9):2711-2720 (1996)
L	A29*	Dandrige et al. J. Med. Chem. 27:28 (1984)
	A30*	Diez-Sampedro et al., "Galactose transport inhibition by cytochalasin E in rat
LCM		intestine in vitro," Can. J. Physiol. Pharmacol. 77(2):96-101 (1999)
1.611	A31*	Duport et al., "An in vitro blood-brain barrier model: Cocultures between endothelial
LCM		cells and organotypic brain slice cultures," <i>Proc. Natl. Acad. Sci. USA</i> 95(4):1840-
		1845 (1998)
	A32*	Earles et al., "Multisubstrate mechanism for the inward transport of dopamine by the
LCM		human dopamine transporter expressed in HEK cells and its inhibition by cocaine,"
		Synapse 33(3):230-238 (1999)
	A33	Fernandez et al., "Synthesis and biological studies of glycosyl donamine deriviatives."
		Carbohyd. Res. 327:353-365 (2000)
LCM	A34*	Figlewicz, "Endocrine regulation of neurotransmitter transporters," Epilepsy Res. 37(3):
		203-210 (1999)

DUP

Examiner Signature: Lucin C. Maur Date Considered: Q-24-07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### **ATTORNEY DOCKET NO. 09172.0006U1** Application Serial No. 10/625,645 SHEET 3 OF X 8

### **INFORMATION DISCLOSURE** STATEMENT LIST

(Use as many sheets as necessary)

	Comple	ete if Known
	Application Number	10/625,645
	Filing Date	July 22, 2003
	First Named Inventor	Samual Christian
	Group Art Unit	1623
	Examiner Name	Leigh C. Maier

LCM	A35*	Findlay et al., "Inhibition of glycosidases by aldonolactones or corresponding configuration.  2. Inhibitors of b-N-acetylglucosaminidase," Biochemical J. 69:467-476 (1958)
LCM	A36*	Fischer et al., "5-Hydroxytraptamine stimulates glucose transport in cardiomyocytes via a monoamine oxidase-dependent reaction," <i>Biochem. J.</i> 311(2):575-583 (1995)
LCM	A37*	Fodor et al., Acta Chim. Acad. Sci. Hung. 28(4):409 (1961)
LCM	A38*	Freeman et al., "In: Chemical Regulation of Biological Mechanisms", Eds., Crieghton, A.M. and S. Turner. Royal Soc. Chemistry, London. pp 154-165 (1982)
LCM	A39*	Gainetdinov et al., "Functional hyperdopaminergia in dopamine transporter knock-out mice," Biol. Psychiatry 46(3):303-311 (1999)
LCM	A40*	Gee et al., "Quercetin glucosides interact with the intestinal glucose transporter pathway," Free Radic. Biol. Med. 25(1):19-25 (1998)
LCM	A41*	Gerding et al., "Metabolism and disposition of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5_hydroxytetraline in conscious monkeys after subsequent iv, oral and ocular administration," <i>Drug. Metab. Dispos.</i> 18(6):923-928 (1990)
LCM	A42*	Geurts et al., "Assessment of striatal D1 and D2 dopamine receptor-G protein coupling by agonist-induced [35S]GTP gamma S binding," Life Sci. 65(16):1633-1645 (1999)
LCM	A43*	Giros et al., "Cloning and functional characterization of a cocaine-sensitive dopamine transporter," FEBS Lett. 295:149-154 (1991)
LCM	A44*	Giros et al., "Cloning, pharmacological characterization and chromosome assignment of the human dopamine transporter," Mol. Pharmacol. 42(3):383-390 (1992)
LCM	A45	Glinsky et al. Inhibition of colony formation in agarose of metastatic human breast carcinoma and melanoma cells by synthetic glycoamine analogs Clin. Exp. Metastasis 14:253-267 (1996)
רכא	A46*	Green et al., "Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein," <i>Drug Metab. Dispos.</i> 24(3):356-363 (1996)
LCM	A47*	Haspel et al., "Effects of barbiturates on facilitative glucose transporters are pharmacologically specific and isoform selective," J. Membr. Biol. 169(1):45-53 (1999)
LCM	A48*	Hibert et al., "Graphics coputer-aided mapping as a predictive tool for drug design: Development of potent, selective and stereospecific ligands for the 5-HT1A receptor," J. Med. Chem. 31:1087-1093 (1988)
LCM	A49*	Horton, "Monosaccharide Amino Sugars. In: "The Amino Sugars": The Chemistry and Biology of Compounds Containing Amino Sugars. Vol. 1A. Ed. R.W. Jeanloz. Academic Press. N.Y. pp. 4-18 (1969)
LCM	A50*	Hurtig, "Problems with current treatment of Parkinson's disease," Exper. Neurol. 144:10-16 (1997)
LGM	A51*	Husbands et al., "Structure-activity relationships at the monoamine transporters as sigma receptors for a novel series of 9-[3-(cis,5-dimethyl-1-piperazinyl)propyl] carbazole (rmicazole) analogues," J. Med. Chem. 42 (21): 4446-4455 (1999)
LCM	A52*	Hyson et al., "Calcium channel blockers modify jejunal uptake of D-galactose in rabbits,"  Dig. Dis. Sci. 41(9):1871-1875 (1996)
LCM	A53*	Hyson et al., "A high cholesterol diet blocks the effect of calcium channel blockers on the uptake of sugars in rabbit intestine," Can. J. Physiol. Pharmacol. 75(1):57-64 (1997)
LCM	A54*	Iorio et al., "Benzazepines structure-activity relationships between D1 receptor blockade and selected pharmacological effects," In: Neurobiology of Central D1 Dopamine Receptors, Eds., G.R. Breese and I. Creese, Plenum Press, NY. pp. 1-14 (1986)
Evamine	r Signatur	

Examiner Signature: Date Considered: 9-24-07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### **ATTORNEY DOCKET NO. 09172.0006U1** Application Serial No. 10/625,645 SHEET 4 OF X &

### **INFORMATION DISCLOSURE** STATEMENT LIST

(Use as many sheets as necessary)

	<u> </u>			
Complete if Known				
Application Number	10/625,645			
Filing Date	July 22, 2003			
First Named Inventor	Samual Christian			
Group Art Unit	1623			
Examiner Name	Leigh C. Maier			

	,	
LCM	A55*	Jaber et al., "Differential regulation of tyrosine hydroxylase in the basal ganglion of micre lacking the dopamine transporter," Eur. J. Neurosci. 11(10):3499-3511 (1999)
	A56	Jakas et al., "Syntheis and CNMR investigation of novel Amadori compounds (1-amino-
104	7.50	1 decays D. fractore derivatives) related to the anicid neutite leaving.
LCM		1-deoxy-D-fructose derivatives) related to the opioid peptide, leucine-enkephalin," J.
	1.57	Chem. Soc., Perkin Trans. 2:789-794 (1996)
LCM	A57	Jiang et al., "Dopaminergic properties and experimental anti-Parkinsonian effects,"
		Clin. Neuropharmacol. 27(2):63-73 (2004)
LCM	A58*	Jones et al., "Dopamine neuronal transport kinetics and effects of amphetamine," J.
LL/VI	İ	Neurochem. 73(6):2406-2414 (1999)
1 0	A59*	Jork et al., "The influence of dopamine on the incorporation of different sugars into total
LCM		proteins of hippocampal slices," Pharmacol. Biochem. Behav. 13(21):303-304 (1980)
LCM	A60*	Kaiser et al., J. Med. Chem. 25:697 (1982)
	A61*	Kawasaki et al., "The identification of two N-acyldopamine glucosides in the left
LCM	Au	collectorial claded of the market of two N-acytopamine glucosides in the left
		colleterial gland of the praying mantid, Tenodera aridifolia sinensis Saussure, and their
	1.624	role in the oothecal sclerotization insect," Biochem. 13:267-271 (1983) Insect Biochem
LCM	A62*	Kerwin et al., "Negative ion electrospray mass spectrometry of polyphenols,
	ļ	catecholamines and their oxidation products," J. Mass Sprectrom. 31:1429-1439 (1996)
LCM	A63*	Kerwin, "Profiling peptide adducts of oxidized N-acetyldopamine by electrospray mass
		spectrometry," Rapid Commun. Mass Sprectrom. 11:557-566 (1997)
	A64*	Kilbourn et al., "Rapid and differentiallosses of in vivo dopamine transporter (DAT) and
LCM		vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice,"
		Synapse 35(4):250-255 (2000)
1.014	A65*	Kitty et al., "Cloning and expression of a cocaine-sensitive rat dopamine transporter,"
LCM		Science 254(5031):578-579 (1991)
	A66	Knoerzer et al., "Dopaminergic benzo[a]phenanthridines: Resolution and
	$\sim$	pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1
		dopamine receptor agonist," J. Med. Chem. 37:2453-2460 (1994)
1.644	A67*	Kuchel, "Peripheral dopamine in hypertension and associated conditions," J. Hum.
LCM		Hypertens. 13(9):605-615 (1999)
	A68*	Kuipers et al., 5-HT1A vs. D2-receptor selectivity of Flesinoxan and analogous N4-
LCM	1	substituted and N1-arylpiperazines," J. Med. Chem. 40:300-312 (1997)
	A69*	Kurnossi "Chasse transport in having a 1 a 4 a 4 a 4 a 4 a 4 a 4 a 4 a 4 a 4
LCM	AU	Kumagai, "Glucose transport in brain and retina: Implications in the management and
	4 70*	complications of diabetes," Diabetes Metab. Res. Rev. 15(4):261-273 (1999)
LCM	A70*	Leal et al., "The metabolism of CGS15873 in man using stable isotope pattern
	1011	recognition techniques," Biopharm. Drug Dispos. 13(8):617-628 (1992)
	A71*	Lichtenthaler, F.W. "Efficient Reaction Channels from Mono- and Disaccharides to
LCM		Enantiopure Building Blocks and Exploitation of Their Application Profiles" In:
. •		Carbohydrates: Synthetic Methods and Applications in Medicinal Chemistry, edited by
		Oqura, H., Hasegawa, A., and Suami, T.Tokyo:Kodansha, p. 3-27 (1992)
LCM	A72*	Liljefors et al., "A molecular mechanics approach to the understanding of
		presynaptic selectivity for centrally acting dopamine receptor agonists of the
		phenylpiperidine series," J. Med. Chem. 29:1896 (1986)
1.044	A73	Likhoshersfov et al., "Sythesis of N-chloroacetyl-ß-glycopyranosylamines, deriviates
LCM		of monosaccharides and lactose," Russ. Chem. Bl. 45:1760-1763 (1996)
LCM	A74	Likhoshersfov et al., Russian Chemical Bulletin, 1998 47(6) page 1214-1217 (abstract)
		, , , , , , , , , , , , , , , , , , ,

DUP

Examiner Signature: Lugh C. Maur | Date Considered: 9-24-07 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### ATTORNEY DOCKET NO. 09172.0006U1 Application Serial No. 10/625,645 SHEET 5 OF X 8

#### **INFORMATION DISCLOSURE STATEMENT LIST**

(Use as many sheets as necessary)

		011551001110			
	Complete if Known				
	Application Number	10/625,645			
	Filing Date	July 22, 2003			
i	First Named Inventor	Samual Christian			
	Group Art Unit	1623			
	Examiner Name	Leigh C. Maier			

Dut

DUP

	105+	T
LCM	A75*	Lostao et al., "Presence of leptin receptors in rat small intestine and leptin effect on sugar absorption," FEBS Lett. 423(3):302-306 (1998)
LCM	A76*	Loland et al., "Defining proximity relationships in the tertiary structure of the dopamine transporter. Identification of a conserved glutamic acid third coordinate in the endogenous Zn2+ binding site," J. Biol. Chem. 274:36928-36934 (1999)
	A77	Maher et al., "Substrate specifically and kinetic parameters of GLUT3," Biochem. J. 315:827-831 (1996)
4	A78*	Manzi et al., "In: Glycobiology: A Practical Approach," Eds. M. Fukuda and A. Kobata. IRL Press, Oxford University, Oxford. p. 29-31 (1993)
LCM	A79*	Martin et al., "Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption," Nat. Genet. 12(2):216-220 (1996)
LCM	A80	Mathews et al. Biochemistry. Second Edition. The Benjamin/Cummings Publishing Company, Inc. p. 286 (1996)
LCM	A81*	Mattiuz et al., "Disposition and metabolism of olanzapine in mice, dogs and rhesus monkeys," <i>Drug Metab. Dispos.</i> 25(5):573-583 (1997)
LCM	A82*	McDermed et al., "Enantioselective binding of (+) and (-) 2-amiono-6,7-dihyroxy-1,2,3,4-tetrahydronaphythalenes and related agonists to dopamine receptors," In: Catecholamines: Basic and Clinical Fronteins, Eds., E. Usdin, I.J. Kopin and J. Barchas, Pergamon Press, NY. p. 568-570 (1978)
~	A83	Meiergerd et al., "Striatal transporter for dopamine," J. Neurochem. 62(3):998-1608
LCM	A84*	Melikian et al., "Membrane trafficking regulates the activity of the human dopamine transporter," J. Neurosci. 19(18):7699-7710 (1999)
LCM	A85	The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 13th Edition 447 1 (Maryadele J. O'Neil et al. Eds. 2001
LCM	A86*	Meyer et al., "Pharmacokinetics and first clinical experiences with an antihypertensive dopamine (DA2) agonist," Eur. Heart J. 13(Suppl. D):121-128 (1992)
במ	A87*	Mico et al., "Function-group metabolism of dopamine-2 agonists: Conversion of 4-(2-di-N-propylamnoethyl)-2-(3H)-indolone to 4-(2-di-N-propylaminoethyl)-7-hydroxyl-2-(3H)-indolone," J. Pharm. Sci. 75(10):929-933 (1986)
LCM	A88*	Miller et al., "Dopamine transporters and neuronal injury," Trends Phramacol. Sci. 20(10): 424-429 (1999)
LCM	A89*	Minor et al., "Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists," J. Med. Chem. 37:4317-4328 (1994)
LCM	A90*	Mizuma et al., "The beta-anomeric and glucose preferences of glucose transport carrier for intestinal active absorption of monosaccharide conjugates," <i>Biochim. Biophys. Acta</i> 1200(2):117-122 (1994)
LCM	A91	Mizuma et al., "Intestinal active absorption of sugar-conjugated compounds by glucose transport system: Implications for improvement of poorly absorbable drugs," <i>Biochem. Pharmacol.</i> 43:2037-2039 (1992)
LCM	A92	Mizuma et al., "Comparative study of active absorption by the intestine and disposition of anomers of sugar-conjugated compounds," <i>Biochem. Pharmacol.</i> 45(7):1520-1523 (1993)
LCM	A93*	Morgan et al., "N-b-Alanylnorepinephrine: Biosynthesis in insect cuticle and possible role in sclerotization," Insect Biochem. 17: 255-263 (1987)

Examiner Signature: Leigh C. Marer Date Considered: 9-24-07 EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#### ATTORNEY DOCKET NO. 09172.0006U1 Application Serial No. 10/625,645 SHEET 6 OF X8

## **INFORMATION DISCLOSURE** STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known		
Application Number	10/625,645	
Filing Date	July 22, 2003	
First Named Inventor	Samual Christian	
Group Art Unit	1623	
Examiner Name	Leigh C. Maier	

DUP

ty in
0:131-
ve
thesis.
3, in
nigh
ett. 9
f
34-287
A
ictose-
-89
riatal
ding,"
re-
551
he
ol
ег
i i

Examiner Signature: herant. Mary Date Considered: 9-24-07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# ATTORNEY DOCKET NO. 09172.0006U1 Application Serial No. 10/625,645 SHEET 7 OF X 8

# INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

	Complete if Known		
	Application Number	10/625,645	
	Filing Date	July 22, 2003	
	First Named Inventor	Samual Christian	
	Group Art Unit	1623	
į	Examiner Name	Leigh C. Maier	

	A113*	Shindo et al., "Metabolism of D- and L-isomers of 3,4 dihydroxyphenylalanine (DOPA).
LEM		V. Mechanism of intestinal absorption of carbon-14 labeled D- and L-doba in rats,"
		Chem. Pharm. Bull. 21(9):2031-2038 (1973)
LCM	A114*	Shah et al., "(+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: Novel
LLM	<u> </u>	dopamine D1 receptor antagonists," J. Med. Chem. 39:3423-3428 (1996)
LCM	A115	Shukla et al., "Effect of desoxy-fructose derivatives of dopa and dopamine on body
		temperature," Archiv für Arzneitherapie 5(1):183-195 (1981)
	A116*	Snyder et al., "Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro1H-
LCM		benzo[6,7]cycloheptal [1,2,3ef][3]benzazepine, 6,7-dihydroxy-2,3,4,8,9,12b-
		hexahydroanthra-[10,4a,4-c,d]azepine and 10-(aminomethyl)- 9,10-
ľ		dihydro-1,2-dihyroxyanthracene as conformationally restricuted analogs of b-
	1110+	phenyldopamine," J. Med. Chem. 38:2395-2409 (1995)
l	A117*	Storch et al., "HEK-293 cells expressing the human dopamine transporter are
LCM		susceptible to low concentrations of 1-methyl-4-phenylpuridine acting via impairment
<del> </del>	A 110#	of energy metabolism," Neurochem. Int. 35(5):393-403 (1999)
LCM	A118*	Sugamori et al., "A cognate dopamine transporter-like activity endogenously
	A 110	expressed in a COS-7 kidney derived cell line," FEBS Lett. 451(2):169-174 (1999)
	A119	Tamai et al., "Transporter-mediated permeation of drugs," J. Pharm. Sci. 89(11):1371-
<b>—</b>	A120	1388 (2000)
LCM	A120	Takata et al., "Transport of glucose across the blood-tissue barriers," Int. Rev.
	A121	Cytology 172:1-53 (1997)
1		Tarjanyi et al. "Chromatographic investigation and computer simulation of (-)deprenyl metabolism," New Approaches Chromatog. 243-266 (1993)
LCM	A122*	Umegae et al., Anal. Chim. Acta 208:59 (1988)
<u> </u>	A123*	
LCM	H123	van de Waterbeemd et al., "Quantitative structure-activity relationships and eudismic
	A124*	analyses of the presynaptic dopaminergic," J. Med. Chem. 30:2175 (1987)
1 014	A124	Vandenbergh et al., "A human dopamine transporter cDNA predicts reduced
LCM		glycosylation, displays a novel repetitive element and provides racially-dimorphic Taql RFLPs," Brain Res. Mol. Brain Res. 15(1-2):161-166 (1992)
	A125	Vannucci et al., "Glucose transporter expression in brain: Relationship to
LCM		cerebral glucose utilization," Dev. Neurosci. 20(4-5):369-379 (1998)
	A126* ·	Verhoeff et al., "Radiotracer imaging of dopaminergic transmission in
LCM		neuropsychiatric disorders," Psychopharmacol. (Berl) 147(3):217-249 (1999)
	A127*	Wang et al., "Conjugation patterns of endogenous plasma catecholamines in
LCM		human and rat," J. Lab. Clin. Med. 101(1):141-151 (1983)
1 644	A128*	Wang et al., "Cathecholamine glucuronidation: An important metabolic pathway for
LCM	<u>L</u>	dopamine in the rat," J. Neurochem. 40(5):1435-1440 (1983)
LCM	A129*	Weinstock et al., Drugs Future 10:645 (1985)
	A130*	Whitfield et al., "Acceleration of sugar transport in avian erythrocytes by
LCM		catecholamines," J. Biol. Chem. 249(13):4181-4188 (1974)
LCM	A131*	Wright et al., "Regulation of Na+/glucose cotransporters," J. Exp. Biol. 200(2):287-
		293 (1997)
LCAA	A132*	Wu et al., "Molecular cloning of the mouse dopamine transporter and
LCM		pharmacological comparison with the human homologue," Gene 233(1):163-170
L		(1999)

DUP

DUP

Examiner Signature: Luch C. Maur | Date Considered: 9-24-07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## ATTORNEY DOCKET NO. 09172.0006U1 Application Serial No. 10/625,645

SHEET 8 OF X S

### **INFORMATION DISCLOSURE** STATEMENT LIST

(Use as many sheets as necessary)

	OHEET OOL NO		
Comple	Complete if Known		
Application Number	10/625,645		
Filing Date	July 22, 2003		
First Named Inventor	Samual Christian		
Group Art Unit	1623		
Examiner Name	Leigh C. Maier		

Dup
-----

(1997)	smin uptake by rat tumors," Int. J. Oncol. 11:497-507			
Examiner Signature: Leigh C. Maur				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and net considered. Include copy of this form with next communication to applicant.				